|
NL188581C
(nl)
*
|
1974-07-15 |
1992-08-03 |
Akzo Nv |
Werkwijze voor het bereiden van 11beta-hydroxy-18-alkylestraanverbindingen.
|
|
ZA763131B
(en)
*
|
1975-05-27 |
1978-01-25 |
Syntex Inc |
Use of flunisolide to treat respiratory diseases
|
|
SE8008524L
(sv)
*
|
1980-12-04 |
1982-06-05 |
Draco Ab |
4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
|
|
IT1196142B
(it)
*
|
1984-06-11 |
1988-11-10 |
Sicor Spa |
Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
|
|
SE8604059D0
(sv)
*
|
1986-09-25 |
1986-09-25 |
Astra Pharma Prod |
A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
|
|
GR1001529B
(el)
*
|
1990-09-07 |
1994-03-31 |
Elmuquimica Farm Sl |
Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
|
|
SE9100341D0
(sv)
*
|
1991-02-04 |
1991-02-04 |
Astra Ab |
Novel steroids
|
|
RU95115547A
(ru)
*
|
1993-01-08 |
1997-06-10 |
Астра Актиеболаг (SE) |
Стероидные соединения, способы их получения и фармацевтический препарат
|
|
DE19635498A1
(de)
*
|
1996-09-03 |
1998-03-26 |
Byk Gulden Lomberg Chem Fab |
Verfahren zur Epimerenanreicherung
|
|
IT1291288B1
(it)
|
1997-04-30 |
1999-01-07 |
Farmabios Srl |
Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
|
|
US6266556B1
(en)
|
1998-04-27 |
2001-07-24 |
Beth Israel Deaconess Medical Center, Inc. |
Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
|
|
IL144900A
(en)
|
2001-08-14 |
2013-12-31 |
Neurim Pharma 1991 |
Melatonin and medicaments comprising it for use in treating primary insomnia and in the manufacture of such medicaments
|
|
AR045536A1
(es)
*
|
2003-08-29 |
2005-11-02 |
Ranbaxy Lab Ltd |
Inhibidores de la fosfodiesterasa tipo -iv
|
|
US20070259874A1
(en)
*
|
2003-11-26 |
2007-11-08 |
Palle Venkata P |
Phosphodiesterase Inhibitors
|
|
WO2005100356A1
(fr)
|
2004-04-09 |
2005-10-27 |
Merck & Co., Inc. |
Inhibiteurs de l'activite d'akt
|
|
EP1888050B1
(fr)
|
2005-05-17 |
2012-03-21 |
Merck Sharp & Dohme Ltd. |
Acide cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl) cyclohexanepropanoique pour le traitement du cancer
|
|
US7915286B2
(en)
|
2005-09-16 |
2011-03-29 |
Ranbaxy Laboratories Limited |
Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
|
|
EP1948167A1
(fr)
*
|
2005-10-19 |
2008-07-30 |
Ranbaxy Laboratories, Ltd. |
Compositions d'inhibiteurs de la phosphodiesterase de type iv
|
|
RU2008119323A
(ru)
|
2005-10-19 |
2009-11-27 |
Рэнбакси Лабораториз Лимитед (In) |
Фармацевтические композиции мускаринового рецептора
|
|
EP2066661A2
(fr)
*
|
2006-09-22 |
2009-06-10 |
Ranbaxy Laboratories Limited |
Inhibiteurs de phosphodiesterase
|
|
JP2010504323A
(ja)
*
|
2006-09-22 |
2010-02-12 |
ランバクシー ラボラトリーズ リミテッド |
Iv型ホスホジエステラーゼの阻害物質
|
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
|
CA2674084C
(fr)
|
2006-12-26 |
2013-05-14 |
Pharmacyclics, Inc. |
Procede d'utilisation des inhibiteurs de l'histone desacetylase et de suivi des biomarqueurs dans une therapie combinee
|
|
EP2805945B1
(fr)
|
2007-01-10 |
2019-04-03 |
MSD Italia S.r.l. |
Indazoles substitués d'amide en tant qu'inhibiteurs PARP de poly(ADP-ribose)polymérase
|
|
US20080207659A1
(en)
*
|
2007-02-15 |
2008-08-28 |
Asit Kumar Chakraborti |
Inhibitors of phosphodiesterase type 4
|
|
US20110130403A1
(en)
*
|
2007-03-14 |
2011-06-02 |
Ranbaxy Laboratories Limited |
Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
|
|
SI2124944T1
(sl)
*
|
2007-03-14 |
2012-05-31 |
Ranbaxy Lab Ltd |
Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze
|
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
|
ITMI20080645A1
(it)
|
2008-04-11 |
2009-10-12 |
Ind Chimica Srl |
Procedimento per la preparazione di budesonide
|
|
EP2111861A1
(fr)
|
2008-04-21 |
2009-10-28 |
Ranbaxy Laboratories Limited |
Compositions d'inhibiteurs de type IV de la phosphodiestérase
|
|
GB0900484D0
(en)
|
2009-01-13 |
2009-02-11 |
Angeletti P Ist Richerche Bio |
Therapeutic agent
|
|
US8691825B2
(en)
|
2009-04-01 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of AKT activity
|
|
US8603521B2
(en)
|
2009-04-17 |
2013-12-10 |
Pharmacyclics, Inc. |
Formulations of histone deacetylase inhibitor and uses thereof
|
|
BR112012005503B1
(pt)
*
|
2009-09-11 |
2021-10-13 |
Chiesi Farmaceutici S.P.A. |
Derivados de isoxazolidina
|
|
GB0916608D0
(en)
|
2009-09-22 |
2009-11-04 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
EP2488028B1
(fr)
|
2009-10-14 |
2020-08-19 |
Merck Sharp & Dohme Corp. |
Pipéridines substituées qui accroissent l'activité de p53 et utilisations de ces composés
|
|
JP2013518909A
(ja)
|
2010-02-08 |
2013-05-23 |
キナゲン,インク. |
アロステリックキナーゼ阻害が関係する治療方法および組成物
|
|
WO2011163330A1
(fr)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
|
|
CN107090456B
(zh)
|
2010-08-02 |
2022-01-18 |
瑟纳治疗公司 |
使用短干扰核酸的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1基因表达的抑制
|
|
JP2013537423A
(ja)
|
2010-08-17 |
2013-10-03 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いたB型肝炎ウイルス(HBV)遺伝子発現のRNA干渉媒介性阻害
|
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
|
WO2012030685A2
(fr)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
|
|
EP2615916B1
(fr)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
|
|
DK2632472T3
(en)
|
2010-10-29 |
2018-03-19 |
Sirna Therapeutics Inc |
RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
|
|
WO2012087772A1
(fr)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
|
|
EP2699568A1
(fr)
|
2011-04-21 |
2014-02-26 |
Piramal Enterprises Limited |
Forme cristalline d'un sel d'un dérivé de morpholinosulfonylindole et son procédé de préparation
|
|
RU2609833C2
(ru)
|
2011-09-13 |
2017-02-06 |
Фармасайкликс Элэлси |
Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
|
|
WO2013063214A1
(fr)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Nouveaux composés qui sont des inhibiteurs d'erk
|
|
EP2844261B1
(fr)
|
2012-05-02 |
2018-10-17 |
Sirna Therapeutics, Inc. |
Compositions de petit acide nucléique interférent (sina)
|
|
JP6453218B2
(ja)
|
2012-08-24 |
2019-01-16 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
疾患を治療するためのhif活性の複素環式修飾物質
|
|
US9155747B2
(en)
*
|
2012-09-13 |
2015-10-13 |
Chiesi Farmaceutici S.P.A. |
Isoxazolidine derivatives
|
|
CN105050598B
(zh)
|
2012-09-28 |
2018-04-27 |
默沙东公司 |
作为erk抑制剂的新型化合物
|
|
RS56680B1
(sr)
|
2012-11-28 |
2018-03-30 |
Merck Sharp & Dohme |
Kompozicije i postupci za lečenje kancera
|
|
US8846657B2
(en)
|
2012-12-20 |
2014-09-30 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as HDM2 inhibitors
|
|
WO2014120748A1
(fr)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
|
|
EP3041938A1
(fr)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Polynucléotides circulaires
|
|
US11066396B2
(en)
|
2016-06-23 |
2021-07-20 |
Merck Sharp & Dohme Corp. |
3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
|
|
US10975084B2
(en)
|
2016-10-12 |
2021-04-13 |
Merck Sharp & Dohme Corp. |
KDM5 inhibitors
|
|
KR20190074310A
(ko)
|
2016-11-08 |
2019-06-27 |
리제너론 파마슈티칼스 인코포레이티드 |
스테로이드 및 이의 단백질-접합체
|
|
CA3063871A1
(fr)
|
2017-05-18 |
2018-11-22 |
Regeneron Pharmaceuticals, Inc. |
Conjugues medicamenteux proteiques a base de cyclodextrine
|
|
JP7426931B2
(ja)
|
2017-11-07 |
2024-02-02 |
レゲネロン ファーマシューティカルス,インコーポレーテッド |
抗体薬物コンジュゲートのための親水性リンカー
|
|
US11098059B2
(en)
|
2017-11-08 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
|
BR112020013492A2
(pt)
|
2018-01-08 |
2020-12-08 |
Regeneron Pharmaceuticals, Inc. |
Esteroides e conjugados de anticorpo dos mesmos
|
|
KR20210008008A
(ko)
|
2018-05-09 |
2021-01-20 |
리제너론 파마슈티칼스 인코포레이티드 |
항-msr1 항체 및 이의 사용 방법
|
|
CA3108388A1
(fr)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de prmt5
|
|
EP3833668B1
(fr)
|
2018-08-07 |
2025-03-19 |
Merck Sharp & Dohme LLC |
Inhibiteurs de prmt5
|
|
EP3833667B1
(fr)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Inhibiteurs de prmt5
|
|
WO2020033285A1
(fr)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de prmt5
|
|
EP4076460B1
(fr)
|
2019-12-17 |
2026-01-21 |
Merck Sharp & Dohme LLC |
Dérivés de 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine] en tant qu'inhibiteurs de prmt5 pour le traitement du cancer
|
|
JP7589247B2
(ja)
|
2019-12-17 |
2024-11-25 |
メルク・シャープ・アンド・ドーム・エルエルシー |
Prmt5阻害剤
|
|
WO2021126728A1
(fr)
|
2019-12-17 |
2021-06-24 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de prmt5
|
|
GEAP202516720A
(en)
|
2022-09-02 |
2025-07-10 |
Merck Sharp & Dohme Llc |
Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
|
|
IL320396A
(en)
|
2022-10-25 |
2025-06-01 |
Merck Sharp & Dohme Llc |
Charge-linkers of anti-drug conjugates derived from extacan, pharmaceutical compositions, and uses thereof
|
|
US20240207425A1
(en)
|
2022-12-14 |
2024-06-27 |
Merck Sharp & Dohme Llc |
Auristatin linker-payloads, pharmaceutical compositions, and uses thereof
|